Tag:
ZymoGenetics
Latest Headlines
Latest Headlines
Report: Bristol exec nabbed on insider trading charge
Bristol-Myers Squibb was having a very bad day today. As its stock was falling in the wake of the news that its $2.5 billion hep C drug may not be worth $2.50, one of its executives was charged with insider trading ahead of three key acquisitions, according to a report from Bloomberg.
ZymoGenetics turns in stellar IIa data on melanoma program
Bristol-Myers Squibb landed a big bonus from ZymoGenetics this morning. Just weeks after the Seattle-based biotech agreed to an $885 million buyout offer, the smaller biotech announced some
BMS forges $885M deal to buy ZymoGenetics
Bristol-Myers Squibb has struck a deal to buy Seattle-based ZymoGenetics for $885 million, snaring its development partner on a mid-stage hepatitis C program along with a pipeline that includes new
ZymoGenetics forges $182M antibody deal with Novo
Antibodies make up one of the hottest markets for new therapeutics. For example, Novo Nordisk is slapping down $24 million in upfront cash and promising up to $157.5 million more to ZymoGenetics for
ZymoGenetics halts immunology work, cuts 52 jobs
ZymoGenetics is cutting all of its immunology work along with 15 percent of its jobs, or 52 positions. That's in addition to the 161 jobs the developer cut in April when it decided to bow out of the
Investigators suspend trial of ZymoGenetics' drug
There's more bad news for ZymoGenetics' experimental drug atacicept this morning. The developer ( ZGEN ) announced that Merck Serono has decided to suspend clinical trials of the drug as a treatment
ZymoGenetics, Immunomedics shares rise on HGS lupus data
The prospect of a new lupus drug hitting the market after decades without a new treatment for the autoimmune disease obviously has Human Genome Sciences investors excited --the company's stock has
ZymoGenetics chops 161 jobs, narrows R&D
Seattle-based ZymoGenetics is taking out the budget axe and chopping 161 jobs, one third of its workforce, as the biotech restructures its R&D effort in order to reduce costs by about $30 million
ZymoGenetics scores mega-deal with BMS
Seattle-based ZymoGenetics scored a blockbuster deal with Bristol-Myers Squibb for its hepatitis C therapy PEG-interferon lambda. The biotech's stock soared 35 percent on the news that it would
ZymoGenetics shares plunge after risks halt trial
Shares of ZymoGenetics were battered yesterday after the company announced that Merck KGaA had discontinued a trial on a partnered therapeutic after researchers noted a high risk of infection for
